(NQ: )

N/A UNCHANGED

Last Price Updated: Add to My Watchlist

Price and Volume

Volume	0
Open	-
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	30.24
Today's Range	N/A - N/A
52wk Range	N/A - N/A
Shares Outstanding	N/A
Dividend Yield	N/A

Chart for (: )

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

Jazz Pharmaceuticals plc Announces Results of Tender Offer to Purchase All of The Outstanding Shares of Common Stock of Celator Pharmaceuticals, Inc.

July 11, 2016

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the results of its tender offer to purchase all of the outstanding shares of common stock of Celator Pharmaceuticals, Inc. (NASDAQ: CPXX) at...

Hercules Announces Strong Third Quarter Financial Results With $0.32 NII Per Share and a $0.31 Quarterly Dividend

November 03, 2016

Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the leading specialty financing provider to innovative venture growth stage companies backed by leading venture capital firms, today...

Performance

More News

Hercules’ Portfolio Update for Q3 2016 Highlights Continued Execution of Its Portfolio and Earnings Growth Strategy

October 04, 2016

Hercules’ Leading Originations Platform Continues to Finance Some of the Most Promising Innovative and Disruptive Venture-Backed Companies in the Market

September 14, 2016

Jazz Pharmaceuticals Announces Expiration of HSR Waiting Period for Proposed Celator Pharmaceuticals, Inc. Acquisition

June 26, 2016

Drugs - Generic Stocks Technical Data - Allergan, Mylan, Horizon Pharma, and Celator Pharma

June 17, 2016

Hercules Provides Portfolio Update for Q2 2016 and Highlights Continued Execution of Its Portfolio and Earnings Growth Strategy

July 05, 2016

Celator Pharmaceuticals® Announces Positive Results in Patients with FLT3 Mutation from the Phase 3 Trial in High-Risk Acute Myeloid Leukemia

June 14, 2016

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Celator Pharmaceuticals, Inc. - CPXX

June 08, 2016

Celator Pharmaceuticals® Presented Phase 3 Trial Results in Patients with High-Risk Acute Myeloid Leukemia Demonstrating VYXEOS™ (CPX-351) Significantly Improved Overall Survival

June 06, 2016

BRIEF-Jazz Pharmaceuticals says majority of Celator's outstanding shares has been validly tendered

July 11, 2016

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.